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Abstract
Although oral squamous cell carcinoma accounts for only a small proportion of malignant neoplasms in the UK, oral cancer
incidence and mortality rates have been rising in recent years. The natural history of oral cancer is not adequately understood at
present and there is very little information about the epidemiology of precancerous lesions in the UK. There are also insucient
data to provide firm evidence that the percentage of cases arising de novo is greater in the UK and the Western world as compared
to the Indian subcontinent. Screening for oral cancer by visual examination is simple, inexpensive and causes little discomfort;
however, there is no evidence for the eectiveness of screening for oral cancer either in reducing mortality from the disease or in
reducing the incidence of invasive disease by detection and treatment of precancerous lesions. There is currently insucient evi-
dence to recommend population screening for oral cancer in the UK. Measures aimed at primary prevention of the disease may be a
more feasible method of disease control at present. # 1998 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Oral cancer is one of the 10 most frequent cancers
worldwide, with about three-quarters of all cases
occurring in the developing countries [1]. In Central and
Southeast Asia it accounts for up to 40% of all cancers,
whereas in most industrialised countries it is relatively
uncommon, accounting for less than 4% [2–4].
Oral cancers constitute only 1–4% of all malignant
neoplasms in the UK [5], but the incidence and mortal-
ity are reported to have been rising in recent years.
Although major advances in reconstructive surgery have
improved the quality of life of patients, there have been
no significant improvements in cure rates in the past few
decades [6]. Other measures are, therefore, necessary to
tackle the rising trends. Primary prevention using health
education is one possibility; screening for oral cancer
has also been suggested [7,8].
The potential benefits of screening are reduced mor-
tality from oral cancer, reduced incidence of invasive
oral cancer, reassurance for those screened negative and
decreased costs of treatment as smaller lesions are easier
to treat with less morbidity [7,9]. Any screening pro-
gramme would also have disadvantages such as psy-
chological trauma for false-positive cases, unnecessary
treatment of precursor lesions which may never have
progressed, false reassurance for false-negatives, and,
not least, the financial costs of setting up the pro-
gramme [7].
In 1993, a UK Working Group on Screening for Oral
Cancer and Precancer concluded that there was insu-
cient evidence to recommend population-based screen-
ing. Opportunistic screening among high-risk groups
attending primary care services was recommended [10].
In 1995, the European School of Oncology’s Advisory
Group on Oral Carcinogenesis to the European Com-
mission for the Europe against Cancer Programme
reported that there was no evidence to support popula-
tion screening [11]. The Group also found it inadvisable
to carry out randomised trials of oral cancer screening
because of deficiencies in the knowledge of the natural
history of oral cancer and the sensitivity and specificity
of current screening tests. Other authors [12] have sug-
gested a systematic reconsideration of data on the nat-
ural history of oral cancer from previous screening
programmes and follow-up studies so as to design a trial
evaluating the eectiveness of screening.
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Prior to considering the implementation of a screen-
ing programme for oral cancer as public health policy in
the UK, it is necessary to examine whether the princi-
ples of screening are fulfilled [13–15] and whether su-
cient research evidence exists for the beneficial eect of
screening and for its cost-eectiveness when compared
with other health interventions [16].
This paper discusses the present situation in the UK,
with particular emphasis on the evidence for and against
population-based screening for oral squamous cell car-
cinoma (ICD9 140, 141, 143–5).
2. Oral cancer in the UK
In England and Wales, the incidence of oral cancer is
4.0 per 100,000 per year at all ages, but over 30.0 per
100,000 among those aged 65 years or more [4]. Inci-
dence and mortality rates have increased in young males
during the last 30 years, a birth cohort eect being seen
in those born after 1911–1912. Females show a similar
trend though of a smaller magnitude; however, no
cohort eect is apparent [17]. New registrations of oral
cancer in 1991 (1815 in all) were 15.6% higher than the
figure reported for 1971 [18]. In 1994, there were a total
of 893 registered deaths due to oral cancer (ICD9 140,
141, 143–5) in England and Wales, of which 61%
occurred in those aged 65 years or more [19].
In Scotland, among men aged 35–64, mouth cancer
(ICD9 143–5) mortality rose from 0.5 per 100,000 in
1971–75 to 1.9 per 100,000 in 1985–1989, while in
women the rate increased from 0.3 per 100,000 to 0.7
per 100,000. Incidence rates showed a similar trend. A
cohort eect was seen for incidence and mortality due to
tongue cancer among males born subsequent to 1910
[20,21].
A rising trend in oral cancer incidence has also been
reported from Northern Ireland among both sexes
though the magnitude is smaller among females
[22,23].
A study conducted to determine the accuracy of oral
cancer reporting found 27% under-ascertainment of
cases at the Thames Cancer Registry and a similar fig-
ure at the South Western Cancer Registry. Warnakula-
suriya et al. suggest that under ascertainment might be a
national problem, the figures for oral cancer in the UK
being actually much higher than reported [24].
The incidence of lip cancers has decreased over the
last three decades among males. However, intra-oral
cancer incidence, particularly that of the tongue and
floor of the mouth, is rising in both sexes though
the changes are less pronounced among females
[18,21,25,26]. In 1991, tongue cancers (ICD9 141)
accounted for about 40% of oral cancer registrations,
mouth cancer (ICD9 143–5) for about 50%, and lip
cancers (ICD9 140) the remaining 10% (Table 1).
Studies of oral cancer mortality according to ethnicity
suggest substantially raised risks (RR=2.2, 95%
CI=1.5–3.1 for males and RR=5.5, 95% CI=3.7–8.2
for females) among ‘ethnic immigrants’ from the Indian
subcontinent as compared to the England and Wales
‘native’ population [27]. The incidence of oral cancer
among ‘Asians’ in Bradford and Leicestershire has been
reported to be higher than in ‘non-Asians’ [28,29].
To conclude, although the absolute number of oral
cancer cases in the UK is small compared to cancers
such as breast cancer and colorectal cancer, the inci-
dence and mortality rates are rising and the number is,
therefore, likely to increase in future. The total number
of oral cancer deaths occurring each year is almost
comparable to the number of deaths due to cervical
cancer. However, oral cancer deaths occur among com-
paratively older age groups [30] and a national screening
programme is operational for cervical cancer which will
already be having an impact on mortality [31].
3. Natural history of oral squamous cell carcinoma
3.1. Risk factors
Both smoked [32–34] and smokeless tobacco [35,36]
are aetiologically linked to oral cancer. Tobacco is also
an important risk factor for pre-cancerous lesions of the
mouth [37–40].
There is evidence that chewing betel quid with
tobacco is carcinogenic to humans [35]. The habit of
betel quid chewing is widespread in Southeast Asia,
Eastern Melanesia, and the East African coast [41] and
remains prevalent in South Asians who migrate to the
UK [27,42], hence increasing the importance of betel
quid as a risk factor in this country.
Elevated levels of alcohol consumption confer size-
able risks of developing oral cancer even after control-
ling for tobacco use [43–45].
Other aetiological factors such as diet [46,47], oral
hygiene and dentition [48,49], mouthwashes [50,51] and
Table 1
Oral cancer registrations in England and Wales (1991)
Site
(ICD9)
Males Females
Number Rate a Number Rate a
Lip (140) 125 0.5 49 0.1
Tongue (141) 464 1.8 273 0.8
Alveolus (143) 71 0.3 52 0.1
Floor of the mouth (144) 246 1.0 81 0.3
Other and unspecified sites (145) 274 1.1 180 0.5
Source: Oce for National Statistics (provisional data).
a Directly age standardised rates per 100,000 population using the
European standard population.
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viral infections [52,53] have also been identified but their
role is inconsistent.
Although tobacco and alcohol are known to be the
major risk factors for oral cancer worldwide, data on
risk factors for oral cancer in the UK are limited. La
Vecchia et al. [54] suggest that alcohol and tobacco
account for about 75% of oral cancers in Europe while
dietary deficiencies or imbalances may account for
about 10–15%.
A comprehensive discussion of the role of primary
prevention in tackling the rising trends of oral cancer
incidence and mortality is beyond the scope of this
paper. However, it is fairly obvious that such activities
should focus on health education to promote the ces-
sation of tobacco use and moderation in alcohol
consumption.
3.2. Precancerous lesions/conditions and malignant
transformation
Both precursor lesions (leukoplakia, erythroplakia)
and a number of pre-cancerous conditions (oral sub-
mucous fibrosis, lichen planus, syphilitic glossitis and
sideropenic dysphagia) are known to exist.
Leukoplakia is the most common precancerous lesion
[55]. The incidence and prevalence of oral leukoplakia
in the UK are not known. However, outside the UK,
the prevalence has been estimated to range from 0.2 to
11.7% [56]. The variation in prevalence between studies
is likely to be due to varying methodology as well
as population dierences in risk factor prevalence.
The minimum degree of whiteness required to define
leukoplakia is arbitrary, and the lesions included in this
group have diered between studies and over time [56–
59]. The prevalence of leukoplakia was shown to vary
between 0.7 and 24.8% in the same population just by
altering the clinical criteria used [58]. In the only popu-
lation-based prospective study (in Kerala, India), the
age-adjusted annual incidence of oral leukoplakia
among 20,358 villagers was reported to be 3.3/1000
among males and 1.9/1000 among females [60]. Leuko-
plakia is more common in males than in females and
usually aects persons older than 40, the average age
being 60 years [61–63].
The risk of malignant transformation is reported to
vary with gender (higher among women), type of leu-
koplakia (higher among those that are idiopathic, non-
homogenous, of a long duration, or situated on the
tongue/floor of the mouth), presence of Candida albi-
cans, and presence of epithelial dysplasia [55]. Hospital-
based series from Europe and USA have reported
malignant transformation rates of 4.4–17.5% for leuko-
plakia, whereas in India, population-based studies
report rates of 0.13–2.2% (Table 2). Estimates of the
percentage of leukoplakias which regress to normal vary
between 4.6% per year in India to 28.6% in the USA. It
is dicult to determine to what extent these dierences
are due to case selection, as opposed to variation in
natural history.
The prevalence of erythroplakia is not known but it is
less common than leukoplakia [64]. In a study of 64,354
cases of potential pre-malignant lesions in the USA,
erythroplakias constituted only 0.09% of the total [65].
Erythroplakia has no apparent sex predilection and
Table 2
Malignant transformation and regression of leukoplakia
Reference Setting Number of
cases
Follow-up Transformation
(%)
Regression
(%)
[134] California, USA hospital 105 1–11 years 6.7 –
[135] San Fancisco, USA hospital leukoplakia
patients
257 mean 7.2 years 17.5 28.6
[136] Amsterdam hospital 84 1–8 years (mean 2.5) 3.6 (3/84) –
leukoplakia patients 46 with available
follow-up
6.5 (3/46)
[137] Stockholm, Sweden hospital 782 1–20 years 4.0 –
[138] Copenhagen, Denmark hospital 248 1–10 years (mean 3.7) 4.4 20.1
[139] Budapest, Hungary hospital 670 1–30 years (mean 9.8) 6 31
[140] Oslo, Norway hospital 157 6–16 years (mean 9.1) 8.9 –
[141] Gujarat, India industrial workers 4,762 2 years 0.13 31.6
[72] Kerala, India field survey 410 1–10 years (mean 7) 2.2 (4.4/1000 p.a.) 4.6 p.a.
Andhra Pradesh, India 1966–77 360 1–10 years (mean 7) 0.3
[142] Kerala, India cohort of 489 homogenous median 4.8 years 1.3/1000 p.a.
tobacco users 13 nodular median 2.8 years 162.2/1000 p.a.
baseline 1977–78 105 ulcerated median 4.4 years 2.2/1000 p.a.
p.a., per annum.
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is more common in the sixth and seventh decades of
life [65,66]. There are no studies reporting follow-up of
series of cases of erythroplakia, perhaps due to its rela-
tively low prevalence or due to more active manage-
ment. Most studies of biopsied cases of erythroplakia
have found that the majority show areas of epithelial
dysplasia, carcinoma in situ or invasive cancer [65,67],
leading most authors to conclude that erythroplakia has
a high potential for malignant transformation. How-
ever, the role of erythroplakia as a precursor lesion as
opposed to an early sign of carcinoma in situ or invasive
cancer is not clear.
Oral submucous fibrosis (OSMF) is a chronic disease
of the oral mucosa which occurs predominantly among
people of Indian origin and occasionally among other
Asians. Sporadic cases have been reported among
non-Asians (Europeans) [68,69]. The prevalence of
OSMF in India ranges from 0.2 to 1.2% [70]. Evidence
for the pre-cancerous nature of OSMF includes the
observation of a higher prevalence of leukoplakia in
cases of OSMF, the occurrence of epithelial dysplasia,
the occurrence of OSMF in oral cancer patients
and the higher incidence of oral cancer in patients
with OSMF [70]. Data from India show increasing
rates of malignant transformation with increasing
duration of follow-up for OSMF (2–3% at 10 years
of follow-up, 4.5% over 15 years, and 7.6% over a
17-year period).
Oral lichen planus (OLP) is a mucocutaneous dis-
order aecting 1–2% of the population in the UK [71];
similar figures have been reported in one study from
India [72]. The malignant potential of OLP has been the
subject of controversy for some time [73], the primary
reasons being a debate over the diagnostic criteria and
definition of OLP, the selection of patients included in
follow-up studies and lack of information on the pre-
valence of OLP in the general population. Its role as a
true precursor lesion remains unclear.
Other pre-cancerous conditions such as sideropenic
dysphagia and tertiary syphilis are now rare in devel-
oped countries [74,75].
3.3. Cancers arising ‘de novo’
The percentage of oral cancers which arise from pre-
cursor lesions is not accurately known, but has been
estimated as more than 75% in India [76]. Although
there are suggestions that the percentage of oral cancer
cases arising de novo is greater in the Western world as
compared to India [77], there are insucient data to
provide firm evidence particularly in countries such as
the UK. Speight and Morgan [64] have calculated that,
based on estimates of prevalence of leukoplakia and
malignant transformation rates from the literature,
progression of leukoplakias could account for the
observed incidence of oral cancer in the UK.
4. Management
4.1. Potentially malignant oral lesions
To date, there are no widely accepted guidelines for
the management of potentially malignant oral lesions in
the UK [40,78,79] and available evidence confirms
variability in the management of these lesions. Marley
et al. [79] reports that only 6% of oral and maxillofacial
surgeons had seen more than 100 patients with such
lesions during the year of study (1993). This may reflect
the referral of these patients to other specialties such as
oral medicine clinics, ENT (ear, nose and throat) sur-
geons, plastic surgeons and radiotherapists or simply
the low number of patients with pre-malignant oral
lesions in the UK. Although the definitive diagnosis of
potentially malignant lesions is based on histopathology
[80,81], only 67% of the consultants biopsied the lesion
routinely at initial presentation, the remaining 33%
presumably relying on clinical appearance as a guide.
The malignant potential of leukoplakia appears to be
associated with the presence of epithelial dysplasia
which is graded by convention as mild, moderate or
severe [82]. The clinical significance of mild and moder-
ate epithelial dysplasia is not known but current evi-
dence suggests that severe epithelial dysplasia has a high
potential for future development of malignancy [83].
A management protocol for potentially malignant
oral lesions proposed by Lamey [78] suggests the elim-
ination of risk factors where possible, followed by a
biopsy and surgical excision of lesions with severe dys-
plasia. For mild–moderately dysplastic lesions, a follow-
up and re-biopsy is suggested after a 3-month period,
with bleomycin or retinoid therapy if dysplasia is
unchanged. A 6-monthly review is suggested for all
patients for their entire life-time.
Most authors seem to agree on the initial approach
suggested by Lamey but dier in their opinions on which
lesions require surgical excision. Tradati et al. [84] suggest
surgical excision of all persistent leukoplakias because of
poor patient compliance with follow-up. Other authors
[55] recommend active treatment for lesions showing
moderate or severe dysplasia, with oral sub-site being the
deciding factor in whether or not to treat mild dysplasia.
In the UK, treatment of mild to moderate dysplasia var-
ies, with 16% of oral and maxillofacial surgeons pre-
ferring no active treatment. For severe dysplasia and
carcinoma in situ, the majority (96%) favoured excision;
however, three (2%) of the clinicians reported not under-
taking any active treatment for these lesions [79].
4.2. Chemoprevention
Retinoids [85–87], b-carotene [88], vitamin E [89] and
Spirulina fusiformis [90] have been shown to produce
regression of oral leukoplakia, but the lesions recur
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soon after stopping the administration of the chemo-
preventive agents.
As no trial has evaluated primary outcome in terms
of reduction in oral cancer incidence and mortality rates
in apparently healthy subjects, it is at present premature
to suggest chemoprevention as a routine strategy to
prevent oral cancers.
4.3. Oral cancer
Treatment in the early stages of oral cancer is a choice
between elective surgery and radical radiotherapy and
depends on factors like the site of the tumour, stage,
previous irradiation, histology and age of the patient.
Preferences vary considerably between treatment
centres, and partly reflect dierences in resources,
expertise, referral patterns and individual clinicians’
opinions [11]. There is no evidence that survival of oral
cancer patients can be improved by chemotherapy.
Formulation of national guidelines for the manage-
ment of potentially malignant oral lesions and oral
cancer, based on current knowledge, is essential to make
the diagnosis and treatment of these lesions consistent
across the UK.
5. Oral cancer prognosis
5.1. Predictors
Tumour stage is a significant predictor of survival,
with prognosis worsening as stage increases [91–94].
Stage has also been found to be related to recurrence
[94].
Several studies have reported an independent prog-
nostic role for tumour diameter with treatment of
lesions less than 2 cm in diameter resulting in a better
prognosis than that of larger lesions [95–98].
Clinical involvement of neck nodes is also a good
marker of prognosis: lymph node negative cases have a
significantly better prognosis than cases with lymph
node involvement [91,96,99,100]. Prognosis has also
been reported to worsen as lymph node involvement
progresses [95,98].
Duration of symptoms and clinical appearance of the
tumour do not seem to have any prognostic significance
when adjusted for other clinical factors [92,95]. Tumour
site has been found to be an independent prognostic
factor in some studies [93,96]. Lip cancers are reported
to have the best prognosis with 5-year survival rates of
85–95% [101,102] whereas for tumours in the oral cav-
ity 5-year survival rates vary from 25 to 60% [95].
Research into the role of histological factors, DNA
ploidy, oncogene expression and other biological
markers has shown that these may complement tumour
stage as prognostic factors, but the results remain
inconclusive at present. These investigations are also
time consuming and require expensive equipment, thus
limiting their clinical use as markers of prognosis. More
prospective research is needed in order to establish the
predictive value of such markers.
5.2. Diagnostic delay
Although the oral cavity permits easy access to visual
examination, most carcinomas of the oral cavity are
not diagnosed until they are symptomatic. By this time
they are larger than 2 cm, regional spread to lymph
nodes already having occurred in 50% of cases
[103,104]. Several authors have reported a median total
delay of approximately 4 months [104–108]. A study in
the UK reported that patient delay in seeking profes-
sional advice was the most important factor delaying
diagnosis [109]. Professional delay can result from fail-
ure on the part of the clinician to conduct a thorough
examination, a low index of suspicion, and lack of
experience with these tumours [104]. In the UK, a mean
delay of 6.4 days from referral to histological diagnosis
and 25.8 days from diagnosis to treatment has been
reported [110]. One study [111] reported that general
practitioners (GPs) diagnosed and referred oral cancer
cases earlier than dental practitioners although the
patient populations examined were similar. Another
[109] found that dental practitioners were less likely
than GPs to suggest a diagnosis of malignancy or to
emphasise the urgency of the consultation in their
referral letters to the specialist. These findings suggest
an important role in the early diagnosis of oral cancer
for GPs in the National Health Service as well as the
need for continuing education among both groups of
practitioners.
6. Screening for oral cancer
Screening for oral cancer and pre-cancer can be car-
ried out by a systematic visual examination of the sur-
face of the oral mucosa. The screening test is, therefore,
relatively simple and inexpensive to perform, and causes
little discomfort to the patient. A detailed examination
protocol, including palpation for lymph nodes has been
described [112] and palpation of the posterior third of
the tongue has also been recommended [10]. The neces-
sity for adequate lighting (standard dental lights) and
the use of dental and laryngeal mirrors have been
recognised [103].
6.1. Compliance
Pilot studies conducted within the UK have shown
that the acceptance of an invitation to oral screening
varies according to the setting.
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A study carried out at a commercial organisation
in London reported a 53% compliance among employ-
ees aged 40 and over, who were invited to attend
for oral screening by a dentist on-site [113]. However,
in a study of the feasibility of conducting oral screening
as part of a routine dental check-up in a comparable
setting to a NHS practice, almost all (1947/1949)
subjects of any age registered with an industrial
dental clinic who were invited to attend for an oral
screen as part of their dental examination agreed to
participate [114]. An invitational screening programme
[115] targeting 4348 subjects (aged 40 and over)
registered with an inner city medical practice in
North London reported that 25.7% of those invited
accepted; a further 8.5% responded after a second
mailing. Of those screened, 12 patients (1.2%) tested
positive, but only eight of these attended the referral
appointment [115].
These results highlight the problem that, whilst the
simplest way to organise screening in the UK may be to
link examinations to dental check-ups, this may not
reach the majority of the population at risk.
In the USA, a survey conducted in 1992 showed that
14.3% of respondents reported ever having an exam-
ination for oral cancer; of these more than half reported
that their most recent examination was as part of a
dental check-up, and more than a third said it was part
of a routine physical examination [112].
Elsewhere, dierent strategies have been used to
recruit subjects for oral cancer screening. A study in
northeast Italy attempted to identify high-risk subjects
(smokers and/or heavy drinkers) attending GP surgeries
and oer them an examination for the early detection of
head and neck cancer. Of 627 subjects identified over a
2-year period only 212 (34%) attended for examination
[116].
In Tokoname, Japan, annual screening of 60-year-old
residents for oral cancer and pre-cancer by postal invi-
tation was begun in 1986 [117]. Of the 5187 individuals
invited betweeen 1986 and 1983, only 802 (15.5%)
attended. Among the variables studied, participation in
screening for other diseases was most strongly asso-
ciated with attendance.
6.2. Validity of the test
The sensitivity and specificity of screening depend on
factors such as the training of the individual perform-
ing the examination, and on the criteria used to deter-
mine which lesions are counted as ‘positive’ and
warrant referral for further investigation. The yield
and positive predictive value depend on the population
screened.
In the UK, examination of the oral cavity has been
reported to have a sensitivity ranging from 71 to 81%
and a specificity of 99% or more when screening
was carried out by general dental practitioners, with
dental specialists’ diagnosis as the gold standard [113,
114,118]. In two studies [113,114], detection of a white
or red patch or ulcer of more than 2 weeks duration
constituted a positive test. The relatively low yield in
one study [114] has been suggested to be due to
the confidence of the screeners in diagnosing frictional
keratosis (counted as a negative test). The fact that
over half the subjects were below age 50 could also
be a factor.
An attempt has been made to use computer-aided
diagnosis, ‘neural networking’, to identify people at
high risk of oral cancer [119]. Using data obtained on 10
risk factors, the ‘network’ correctly identified 80% of
subjects diagnosed by specialists as having positive
lesions, and had a specificity of 77%.
A number of authors have reported on the use of
toluidine blue dye as an adjunct for screening for oral
cancer in order to increase sensitivity by providing bet-
ter demarcation of SCC and dysplastic changes [120]. A
recent study in a clinical series found a sensitivity of
100% for oral cancer and 79.5% for oral epithelial dys-
plasia, but a specificity of only 62.5% [121]. A meta-
analysis [122] of a number of clinical studies estimated
the sensitivity of the test to range from 93.5 to 97.8%,
and the specificity from 73.3 to 92.9%, but there are no
studies of its use in a screening situation.
Table 3 summarises the results of the UK studies:
specificity is high, sensitivity (where measurable) satis-
factory, and values for the yield of positive lesions are
generally high.
Table 3
Sensitivity and specificity of the screening test (UK studies)
Reference Area/country Settting Subjects screened Age Sensitivity
(%)
Specificity
(%)
Yield
(%)
PPV
(%)
[113] London company dental practice 309 40+ 71 99 5.5 86
[114] Wirral industrial dental clinic 1947 20ÿ69 ÿ 100 0.2 100
[118] London dental hospital (out-patients
department)
1042 40+ 81 99 3.1 68
inner-city medical practice 985 64 99 2.2 47
PPV, positive predictive value.
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6.3. Large-scale population screening studies
These have mostly been carried out outside the
UK, in areas where oral cancer is a significant public
health problem. In a number of studies in developing
countries, a major problem with compliance has
been with attendance for referral in those with a
suspicious lesion.
The feasibility of using primary health care workers
for oral cancer screening has been investigated in Sri
Lanka [123]. Of 29,295 individuals (age>20 years)
screened, 1220 (4.2%) had oral lesions warranting
referral [124]. However, only 660 (54.1%) of these sub-
sequently attended re-evaluation by the project dentist
and 384 (58%) had the diagnosis confirmed. Of a sam-
ple of 1212 subjects screened negative and re-examined,
21 (1.7%) were classified as positive. In another study in
Sri Lanka [125], the use of a simultaneous health edu-
cation programme improved compliance with referral to
62% (2193/3559). The detection rates were 35 per
100,000 for new oral cancers, and 30 per 1000 for a true
positive referral. Of 1350 negative cases re-examined
3.8% had ‘referable’ lesions.
In Kerala, India, a sensitivity of 59% and a specificity
of 98% have been reported for screening by Basic
Health Workers and re-examination by dentists [126] .
Of those referred, 72% had attended further examina-
tion, and 45% of these were deemed correctly referred.
In another study in Kerala [127], despite organised
training, only a small percentage of primary health
workers were motivated to carry out screening. They
examined 17,812 subjects (6.5% of those eligible) over a
period of 36 months, but of the 408 referred with sus-
pected lesions only 258 (63.2%) attended for re-exam-
ination. A population-based oral cancer screening trial
aiming to randomise 90,000 individuals to intervention
and control groups was begun in 1995 in Trivandrum,
India. About 32,000 subjects have already been recrui-
ted, and a recent report indicates almost perfect agree-
ment (kappa=0.85) between health workers performing
the oral screen and the reference findings provided by
physicians, in the identification of various oral pre-
cancerous lesions [128].
In Cuba, an oral cancer screening programme has
been in existence since 1984, with the aim of all sub-
jects 515 years of age having an annual oral exam-
ination by a dentist [129]. Between 1984 and 1990, 12–
26% of the population were covered annually, and of
30,244 (0.23%) individuals referred only 28.8% com-
plied. The detection rate for cancers and pre-cancerous
lesions was 0.3 per 1000 screens. A recent paper claims
that a fall in the percentage of stage II–IV cancers
between 1982 and 1988 reflects the eect of this pro-
gram [130]. It is unlikely that treatment of pre-cancer-
ous lesions would have a marked eect within such a
time period. As no rates are presented, the percentages
may simply reflect an increase in the diagnosis of early
stage disease.
6.4. Mouth self-examination (MSE)
The majority of work on early detection of oral can-
cer has been on screening by health professionals. There
is little information about the feasibility of self-screen-
ing, or on health education to promote this. One study
which examined the feasibility of MSE in India reported
that 36% of 22,000 eligible subjects approached had
practised MSE [131]. Among 247 subjects visiting the
clinic within 2 weeks of the promotion (distribution of
brochures regarding MSE), seven new oral cancers and
82 pre-cancerous lesions/conditions were detected.
However, there is no information on longer term uptake
or detection rates.
6.5. Costs of screening
There are no estimates available of the full cost of a
screening programme for oral cancer. Clearly the costs
will vary according to the setting and method of orga-
nisation. The initial examination has been quoted as
taking less than 5 min (e.g. of a dentist’s time). How-
ever, it has been pointed out that the abolition of free
dental check-ups in the UK means that the cost of
screening in such a setting would, therefore, be borne by
the population, and would have a detrimental eect on
uptake [132].
Although facilities for the diagnosis and treatment of
potentially malignant and malignant oral lesions exist,
implementation of a population-based screening pro-
gramme on a nationwide scale would be a strain on the
available resources because of the resulting increase in
work-load.
Preliminary results from a simulation model of
population screening for oral cancer and precancer
indicate that approximately 18,000 individuals would
need to be screened in order to save one life [133]. With
an assumed compliance rate of 50%, the net benefit of
screening was the equivalent of 2.8 lives saved. How-
ever, any health gain achieved by screening would be
severely compromised in the presence of low compliance
rates, variable performance (detection rates) by practi-
tioners, and high drop-out rates that might occur in a
programme providing periodic rescreening.
7. Conclusions
Oral cancer incidence and mortality are currently ris-
ing; a cohort eect is seen for males born after 1911–12.
Each year about 2000 new oral cancers (ICD9 140–145)
and 1000 oral cancer deaths are registered in England
and Wales. Although the major risk factors for oral
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cancer are known to be tobacco and alcohol consump-
tion, more information is needed on the risk factors for
oral cancer in the UK, including those in ethnic groups,
and on the reasons for the increasing incidence.
Visual examination appears to be a valid screening
test for oral cancer and pre-cancer, the acceptability of
screening varying according to the setting. There is a
likelihood of selection bias, particularly if screening is
performed in dental practices, with those attending
likely to be a more health-conscious and low-risk
population. In developing countries, whilst acceptance
of initial examination has been good, compliance with
referral by subjects detected positive has often been
poor, and adequate resources may not be available for
follow-up.
Incomplete understanding of the natural history of
precursor lesions makes the classification of positive
cases at screening dicult. Identification of all leuko-
plakias as ‘positive’ is likely to result in considerable
over-diagnosis, but determination of which lesions are
likely to progress involves invasive techniques. In addi-
tion, treatment of leukoplakia does not necessarily pre-
vent progression to invasive cancer.
Further research into the natural history of the dis-
ease would be worthwhile in order to provide better
estimates of the prevalence of pre-cancerous and early
invasive lesions in Western countries. Whilst dentists
may be the most appropriate professionals to conduct
such studies, care needs to be taken to avoid a highly
selected population.
As there are no widely accepted guidelines for the
management of potentially malignant oral lesions in
the UK and available evidence confirms variability
in the management of these lesions by consultant oral
and maxillofacial surgeons, formulation of national
guidelines based on current knowledge is essential to
make the diagnosis and treatment of these lesions con-
sistent across the UK.
Although treatment of early invasive cancer will cause
less morbidity than that of late-stage cancer, and early
stage disease has a better prognosis, there is no evidence
on the eectiveness of population screening for oral
cancer, either in reducing mortality from the disease
or in reducing the incidence of invasive disease by
the detection and treatment of precursor lesions. On the
same basis, there is no justification for opportunistic
screening in general practitioner/dental practitioner
clinics. In addition, this method might not reach indivi-
duals at high risk of disease, as clinic attendees are often
more health conscious, low-risk individuals.
Further research on the eectiveness of screening for
oral cancer, ideally in the form of a randomised trial is,
therefore, necessary before population screening is con-
sidered. The applicability of the results of the on-going
Indian trial [28] to the UK are likely to be limited, both
due to methods of intervention and possible dierences
in natural history. A randomised trial in the general
population in the UK would be prohibitively large with
an estimated sample size in excess of 1.4 million subjects
based on current oral cancer mortality rates among the
general population (=0.05, 80% power to detect a
mortality reduction of 20%). Calculation of sample size
using expected mortality rates among a population
initially free of disease (as in a screening trial setting)
would yield an even higher figure. Although this pro-
blem could be overcome by targeting a sub-group at
suciently increased risk of oral cancer, identification
of such a group (smokers and drinkers aged 40+ years)
would be a dicult task as lifestyle factors are often
dicult to ascertain and people are reluctant to admit
to them [7].
There is currently insucient evidence to recommend
population screening for oral cancer in the UK. Other
measures, particularly eorts aimed at primary preven-
tion of the disease may be a more feasible method of
disease control at present.
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